Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii
- PMID: 20301995
Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii
Abstract
Background: Multidrug-resistant (MDR) Acinetobacter baumannii are increasingly encountered and frequently susceptible only to colistin with their MIC values close to resistance breakpoint. Antibacterial activity of two carbapenem-based combinations were explored in order to overcome the bacterial resistance.
Material and method: Thirty clinical isolates of MDRA. baumannii were employed to assess in vitro antibacterial activity of two carbapenem-based regimens. Imipenem combined with colistin and meropenem combined with colistin and sulbactam were the first and second regimens, respectively. All isolates were resistant to imipenem (MIC range: 8-128 microg/ml) and meropenem (MIC range: 64-256 microg/ml) but still susceptible to colistin (MIC range: 0.5-2 microg/ml). The MIC range of sulbactam was 4-64 microg/ml. None of the isolates produced metallo-beta-lactamase.
Results: Synergistic antibacterial effect of imipenem combined with colistin was observed against 100 percent of A. baumannii isolates by the checkerboard microdilution panel method. In a subsequent time kill study, the most active concentration of this regimen was the combination of imipenem at the fixed concentration of 32 microg/ml and colistin at the 1/4 of the MIC values of each isolate that exerted significantly higher bactericidal activity than imipenem at 32 microg/ml alone and colistin alone at the 1/4 of the MIC values. The scanning electron micrographs demonstrated major cell morphological change and cell wall destruction after 2-hour exposure to this combination. The triple combinations of meropenem, sulbactam and colistin showed synergy against 96.7 percent of MDR A. baumannii while double combinations of either meropenem and sulbactam, meropenem and colistin, and sulbactam and colistin showed synergy effects of 70%, 73.3% and 53.3%, respectively The time kill study using ten isolates also showed better killing effect by the triple combination than any of the double combinations.
Conclusion: Antibacterial activity against MDR A. baumannii of imipenem plus colistin was superior over any single of the two agents. The addition of sulbactam to meropenem and colistin may further improve their antibacterial activity. The double or triple carbapenem-based combinations offer promising alternatives in the treatment of infections due to MDR A. baumannii.
Similar articles
-
Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.Pharmacotherapy. 2007 Nov;27(11):1506-11. doi: 10.1592/phco.27.11.1506. Pharmacotherapy. 2007. PMID: 17963460
-
In vitro activities of tigecycline alone and in combination with colistin sulfate or sulbactam against carbapenem-susceptible and -resistant Acinetobacter baumannii strains isolated from Intensive Care Units.Int J Antimicrob Agents. 2010 Aug;36(2):191-2. doi: 10.1016/j.ijantimicag.2010.04.004. Epub 2010 May 26. Int J Antimicrob Agents. 2010. PMID: 20537868 No abstract available.
-
In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.J Antimicrob Chemother. 2007 Aug;60(2):317-22. doi: 10.1093/jac/dkm136. Epub 2007 May 31. J Antimicrob Chemother. 2007. PMID: 17540672
-
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.J Antimicrob Chemother. 2012 Jul;67(7):1607-15. doi: 10.1093/jac/dks084. Epub 2012 Mar 22. J Antimicrob Chemother. 2012. PMID: 22441575 Review.
-
Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22. Int J Antimicrob Agents. 2012. PMID: 22113193 Review.
Cited by
-
A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis.Antibiotics (Basel). 2022 Aug 17;11(8):1112. doi: 10.3390/antibiotics11081112. Antibiotics (Basel). 2022. PMID: 36009980 Free PMC article.
-
Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infection.Pharmaceutics. 2022 Jun 14;14(6):1266. doi: 10.3390/pharmaceutics14061266. Pharmaceutics. 2022. PMID: 35745838 Free PMC article.
-
In vitro synergistic antimicrobial activity of a combination of meropenem, colistin, tigecycline, rifampin, and ceftolozane/tazobactam against carbapenem-resistant Acinetobacter baumannii.Sci Rep. 2022 May 9;12(1):7541. doi: 10.1038/s41598-022-11464-6. Sci Rep. 2022. PMID: 35534512 Free PMC article.
-
Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Front Cell Infect Microbiol. 2022 Mar 15;12:823684. doi: 10.3389/fcimb.2022.823684. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 35372099 Free PMC article. Review.
-
Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia.Antibiotics (Basel). 2021 Jul 23;10(8):903. doi: 10.3390/antibiotics10080903. Antibiotics (Basel). 2021. PMID: 34438953 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical